Systemic therapies for melanoma brain metastases: which drug for whom and when?

摘要: Melanoma brain metastases are common, difficult to treat, and associated with a poor prognosis. Historically, due the activity of chemotherapeutic agents in melanoma, management was centred on local treatments such as surgery, stereotactic radiosurgery (SRS) or whole radiotherapy (WBRT) depending clinical presentation. New systemic therapies have now evolved; kinase inhibitors targeting BRAF mutated melanoma cells activating checkpoint that activate an immune anti-tumour response, resulting significantly improved survival quality life for patients metastatic these drugs demonstrated metastases. As landscape shifts incorporate new available therapies, further research into using appropriate combinations sequences various treatments, especially active progressing metastasis, is required. This review will examine evidence metastasis (untreated treated progressed) highlight evolving trials this challenging field.